Overview of Nisoldipine

Property	Description
Active ingredient	Nisoldipine
Form	Extended-release (ER) oral tablet
Pharmacological class	Dihydropyridine Calcium Channel Blocker
Origin	Synthetic compound (Second-generation derivative)

Nisoldipine: Core Identity and Pharmacological Classification

Nisoldipine is a synthetic, single-ingredient medication belonging to the pharmacological class of calcium channel blockers (CCBs), specifically identified as a dihydropyridine calcium antagonist. This compound is a second-generation derivative, clinically recognized for its high selectivity for vascular smooth muscle cells. Its classification as a calcium antagonist defines its fundamental mechanism: modulating the entry of calcium ions into specific cells. As a dihydropyridine derivative, its primary physiological focus is on the blood vessel walls.

Composition and Extended-Release Formulation

The sole active agent in this medication is the chemical entity Nisoldipine, which is administered to adult patients via the oral route. Nisoldipine is characterized by its dosage form as an extended-release (ER) tablet or sustained-release (SR) tablet. This specific formulation is a key differentiating factor, deliberately engineered to ensure a steady concentration of the drug is maintained over a prolonged period. The extended-release design utilizes a controlled pharmaceutical matrix to ensure the gradual and consistent absorption of the drug into the bloodstream over many hours, supporting continuous management.

Primary Action and General Physiological Purpose

Nisoldipine's primary action is to induce vasodilation, which is the widening and relaxation of the body's peripheral blood vessels. As a highly vascular-selective CCB, it acts by limiting the movement of calcium ions, a process necessary for muscle contraction, primarily within the cells of the arterial walls. This physiological effect results in a significant reduction in peripheral vascular resistance (PVR). The general purpose of this targeted action is to ease the resistance against which the heart must pump blood, reducing the cardiac workload and supporting overall efficient blood flow dynamics. This action relaxes blood vessels and decreases the heart's pumping effort.

What side effects are possible with Nisoldipine?

Possible Side Effects and Safety Information

This section summarizes the officially documented adverse reactions and safety restrictions for Nisoldipine, based on regulatory health authority documents. This information does not constitute medical advice or instructions for use.

Frequency-Classified Adverse Reactions

Adverse reactions are classified based on the frequency observed in clinical trials, using standardized categories. The most frequently documented side effects (Very Common, ge 1 in 10 patients) are headache and peripheral edema (swelling, usually of the ankles and feet).

Common side effects (from ge 1 in 100 to < 1 in 10 patients) include dizziness, palpitations, vasodilation (flushing), gastrointestinal upset, fatigue, and rash.

Serious and Clinically Significant Safety Events

The medicine's safety profile includes a documented risk of potentially serious cardiac events. In rare instances, particularly when therapy is started or the dose is increased, angina pectoris (chest pain) may be exacerbated, or acute myocardial infarction (heart attack) may be precipitated, especially in patients with pre-existing severe coronary artery disease.

Safety Restrictions and Limitations

Nisoldipine is officially contraindicated (should not be used) if there is a known hypersensitivity or allergic reaction to Nisoldipine or any other dihydropyridine calcium channel blocker.

Due to the drug’s metabolism, it is also contraindicated when co-administered with potent CYP3A4 inhibitors, which can significantly increase Nisoldipine plasma concentrations. This includes certain medications and the consumption of grapefruit juice.

Population-Specific Considerations

Caution and close safety monitoring are necessary for specific patient populations. This includes individuals who are elderly and patients with severe hepatic (liver) impairment, as they may experience reduced drug clearance and higher plasma levels, potentially increasing the risk of adverse reactions.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Nisoldipine, an extended-release calcium channel blocker, is a medical emergency primarily characterized by an exaggerated lowering of blood pressure and effects on the heart. Documented manifestations may include profound hypotension (extremely low blood pressure), and heart rate disturbances such as bradycardia (slow heart rate) or tachycardia (rapid heart rate). Severe toxicity can involve systemic effects like drowsiness, confusion, and potentially progress to life-threatening outcomes such as shock and cardiovascular collapse.

Official Regulatory Guidance

Regulatory authorities mandate immediate action in the event of a suspected overdose. The official instruction is to seek medical help right away and contact the Poison Control Helpline for specific instructions. Emergency services (911) must be called immediately if the person has collapsed, had a seizure, has trouble breathing, or cannot be awakened. Due to the extended-release formulation, the risk of toxicity is prolonged, requiring specific measures and continued hospital monitoring to manage potential delayed effects. Treatment is symptomatic and supportive, as no specific antidote is known.

Therapeutic Uses of Nisoldipine

Nisoldipine: Main Uses and Therapeutic Benefits

Nisoldipine is commonly used for the sustained management of essential hypertension, a condition involving persistent high arterial pressures and symptoms related to systemic imbalance. It is also applied in conditions involving recurrent or episodic manifestations, such as chronic stable angina pectoris.

This therapeutic approach supports the continuous management of blood pressure, which may assist with easing the overall physiological strain on the heart. The medicine is considered relevant in managing conditions where functional stability becomes affected, contributing to the supportive management of systemic stress.

This supportive relief contributes to improved comfort during periods of heightened symptoms and assists with maintaining functional stability when symptoms interfere with routine activities. It helps address symptom clusters related to physical discomfort and systemic imbalance.

Quick Fact: Relief for Sustained Cardiovascular Strain
Common Clinical Scenarios: Long-term management of chronic essential hypertension and supportive management for conditions involving recurrent or episodic manifestations.
Patient Benefit: Provides supportive relief that helps ease the overall symptom burden and assists with maintaining functional stability during symptomatic periods.

Regulatory References

NIH MedlinePlus overview on Nisoldipine

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use Nisoldipine?

This section outlines the official eligibility and non-eligibility requirements for Nisoldipine, as defined by authoritative government regulatory documents.

Absolute Contraindications (Must Not Use)

Nisoldipine is contraindicated and must not be used in the following populations or conditions:

Patients with a known hypersensitivity to Nisoldipine or any other dihydropyridine calcium channel blockers.
Patients experiencing cardiogenic shock, unstable angina, or an acute myocardial infarction.
Concurrent use with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole) due to the risk of dangerously high Nisoldipine levels.
Concurrent use with grapefruit or grapefruit juice.

Conditional or Restricted Use

Geriatric Patients (Elderly): A lower initial dose is required due to increased systemic drug exposure.
Hepatic Impairment: Patients with liver dysfunction must receive a lower initial and maintenance dose due to severely impaired clearance.

Age and Physiological Status

Pediatric Patients: Safety and efficacy in children have not been established.
Pregnancy and Lactation: Use should generally be avoided (Category C); nursing should be discontinued if the medicine is required.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

Nisoldipine is extensively metabolized by the Cytochrome P450 3A4 (CYP3A4) enzyme system. Consequently, the drug's safety and effectiveness can be significantly altered by co-administered substances that affect this enzyme.

Contraindicated or Avoided Combinations

CYP3A4 Inhibitors: Coadministration with strong CYP3A4 inhibitors, such as itraconazole, ketoconazole, and certain others, is contraindicated. These substances prevent the breakdown of nisoldipine, leading to significantly increased plasma concentrations and risk of adverse effects.
Dantrolene: Coadministration is contraindicated due to the enhanced risk of cardiovascular collapse and marked hyperkalemia.
Grapefruit Products: Ingestion of grapefruit or grapefruit juice must be avoided entirely, as it inhibits CYP3A4 in the gut wall, leading to a large increase in nisoldipine systemic exposure.

Other Significant Interactions

CYP3A4 Inducers: Coadministration with strong CYP3A4 inducers, such as phenytoin or rifampin, should be avoided. These agents increase the breakdown of nisoldipine, leading to considerably lower plasma concentrations and potential loss of efficacy.
Food Effect: The drug should be taken on an empty stomach (one hour before or two hours after a meal). Concurrent intake with a high-fat meal is known to alter the drug's absorption profile significantly.

Mechanism of Action

How Nisoldipine Works

Nisoldipine functions as a dihydropyridine calcium channel blocker, affecting the movement of calcium ions in specific muscle cells to modulate physiological responses. The core mechanistic domains involve antagonism of calcium channels and the resulting changes in vascular dynamics.

Inhibition of L-type Calcium Channels

Nisoldipine acts within domains involving voltage-dependent L-type calcium channels (Cav1.2) located on vascular smooth muscle cells. By binding to a specific site, the drug stabilizes these channels in an inactive conformation. This action effectively blocks the transmembrane influx of extracellular calcium ions (Ca^2+) into the cell cytoplasm, thereby modifying the early molecular steps that initiate muscle contraction.

Modulation of Peripheral Vascular Tone

Since the contractile process in vascular smooth muscle is calcium-dependent, the reduction of intracellular Ca^2+ concentration is the central mechanistic cascade. This event leads directly to the relaxation of the smooth muscle. The resulting physiological consequence is vasodilation (widening of blood vessels), which causes an altered state of peripheral vascular resistance and modifies the forces that regulate vascular tone.

Dosage and Administration Information

How Nisoldipine Is Used: Official Administration Guidelines

Nisoldipine is administered exclusively via the oral route as an extended-release (ER) tablet formulation, utilized for long-term, sustained management of chronic conditions. The specific extended-release form requires the tablet to be swallowed whole without crushing, chewing, splitting, or dividing, as physical alteration compromises the controlled-release delivery system.

Dosing and Frequency Principles

Nisoldipine follows a once daily (q.d.) dosing frequency. Treatment initiation and adjustment adhere to a stepwise process. For the newer ER formulation, the standard starting adult dose is 17 mg once daily, with the usual maintenance range extending up to 34 mg once daily, which is also the maximum recommended dose. Dose adjustments are made slowly, often at intervals of at least one week or longer.

Essential Administration Constraints

Constraint Type	Official Requirement
Timing with Meals	The tablet must be taken on an empty stomach (one hour before a meal or two hours after a meal) to maintain correct drug concentration.
Dietary Restriction	Consumption of grapefruit or grapefruit juice must be avoided due to the risk of significantly increasing drug concentration in the bloodstream.

Population-Specific Use

Initial dosing protocols differ for certain populations. The starting dose is lowered to 8.5 mg (newer formulation) or 10 mg (original formulation) once daily for both older adults (geriatric patients) and individuals with hepatic impairment (e.g., cirrhosis). This adjustment is a procedural step when initiating therapy in these groups.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Nisoldipine

Evidence for use in Hypertension (High Blood Pressure)

Nisoldipine was evaluated in studies involving outcomes related to high blood pressure, a condition where symptoms may vary in intensity. Research focused primarily on short-term and intermediate-term randomized controlled trials where outcomes related to changes in blood pressure measures were closely monitored. These studies contained analysis of how blood pressure levels changed over defined time intervals in adult populations.

The findings describe patterns observed in the studies where blood pressure levels evolved in the observed adult populations. The research highlights changes measured during the study period and contributes to the broader evidence landscape regarding how blood pressure was observed in these settings. However, certainty regarding how these patterns hold up over many years remains low, and there is limited information for long-term outcomes.

Evidence for use in Angina Pectoris (Chest Pain)

Nisoldipine was evaluated in studies involving its use for angina pectoris, a condition characterized by fluctuating or episodic manifestations. The research includes controlled trials that contained measures of chest pain and functional activity level. These studies monitored patient experiences during episodes where symptoms become more noticeable.

Long-term Studies and Follow-up Duration

The evidence currently available primarily involves studies with limited follow-up durations. This means that long-term effects are not fully established regarding the use of Nisoldipine. While intermediate-term studies, such as some observational settings, data describe patterns related to outcomes over several months, controlled, randomized research for many years is still emerging. Research is currently insufficient to fully understand the stability of outcomes over time.

Evidence in Special Populations

Evidence has been collected on the use of Nisoldipine in certain populations, such as older adults. However, data for certain groups remain insufficient. For instance, there is little research available for pediatric patients (children) or for pregnancy-related populations. Detailed subgroup findings for patients with severe liver or kidney impairment are uncertain or evidence quality varies across studies. This means results apply only to the populations studied.

What is Still Uncertain About Nisoldipine

The research highlights what is known—and what is still uncertain—about Nisoldipine. A primary gap is that long-term outcomes are not fully established, as follow-up durations were limited in the primary controlled research. Furthermore, the data for certain groups remain insufficient. In some areas, findings were mixed or the evidence quality varies across studies, indicating that certainty remains low for certain endpoints. The research provides context but not individual predictions.

Key Studies & References Long term effects of nisoldipine on the progression of coronary atherosclerosis and the occurrence of clinical events: the NICOLE study (for angina/long-term outcomes and limitations)

Frequently Asked Questions (FAQ)

Common questions about Nisoldipine (FAQ)

Q: What is the main difference between Nisoldipine and other calcium channel blockers?

A: Nisoldipine belongs to the dihydropyridine class of calcium channel blockers. Official documents note it has a high selectivity for relaxing blood vessel walls rather than affecting the heart muscle significantly. It is also distinctive because it is formulated only as an extended-release tablet designed for once-daily use.

Q: Are there any long-term side effects associated with Nisoldipine use?

A: Official studies regarding Nisoldipine have primarily involved limited follow-up periods. Because of this, the long-term effects of the medication are not yet fully established in controlled clinical research. Safety data available focuses on the side effects observed during short- to intermediate-term use.

Q: Can Nisoldipine affect kidney function?

A: Regulatory information indicates that Nisoldipine and its byproducts are primarily eliminated from the body by the kidney. Official drug information notes that data for use in patients with severe kidney impairment is limited.

Q: What kind of blood pressure changes are expected with Nisoldipine?

A: Nisoldipine works to reduce the resistance of blood vessels, leading to a general decrease in blood pressure. According to regulatory documents, the full blood pressure effect is typically observed after a few weeks of consistent use.

Q: Are there specific times of day Nisoldipine is usually recommended to be taken?

A: Nisoldipine is typically taken once a day at the same time every day. Official instructions state that the tablet should be taken on an empty stomach (one hour before or two hours after a meal), but they do not specify whether the morning or evening is generally preferred.

Q: Is Nisoldipine the same as nifedipine?

A: Nisoldipine and nifedipine are both classified in the same family of drugs, the dihydropyridine calcium channel blockers. However, they are distinct drugs with different properties and dosing requirements. Nisoldipine is only available as an extended-release formulation.

Q: How quickly does Nisoldipine start working after I take it?

A: The extended-release formulation of Nisoldipine is designed to release the medication slowly into the bloodstream. Official pharmacological data indicates that the drug reaches its highest concentration in the blood after approximately 9.2 hours on average.

Q: Can Nisoldipine cause weight gain or weight loss?

A: Official safety data for Nisoldipine notes that less common side effects have included reports of unusual weight gain or loss and rapid weight gain. These effects were observed in clinical trials but are not among the most frequently reported.

Q: Does Nisoldipine interact with commonly used over-the-counter pain relievers?

A: Official drug interaction information notes that certain over-the-counter pain relievers known as NSAIDs (such as naproxen or aspirin) may potentially lessen the blood pressure-lowering effect of Nisoldipine. Acetaminophen is generally not listed as a significant interaction.

Q: Can Nisoldipine be taken with supplements like magnesium or potassium?

A: Official advice advises that the use of salt substitutes containing potassium should be discussed with a prescriber. Standard magnesium supplements are not generally listed as a specific restriction in the regulatory documents.

Q: If I miss a dose of Nisoldipine, what is the generally accepted advice?

A: Regulatory information describes that if a dose is missed, it may be taken as soon as it is remembered. If the time is near the next scheduled dose, the missed dose is usually skipped, and the regular schedule continued. Official warnings state that a double dose must not be taken to compensate for a missed dose.

Q: Does alcohol interact negatively with Nisoldipine?

A: Regulatory safety information indicates that consuming alcohol while taking Nisoldipine may increase the risk of certain side effects. This includes central nervous system effects such as dizziness.

Q: Are there any generic versions of Nisoldipine available?

A: Yes, the FDA has approved and authorized a generic version of Nisoldipine extended-release tablets. Generic versions contain the same active ingredient and are available in various strengths.

Q: Is Nisoldipine considered a 'first-line' treatment for high blood pressure?

A: Nisoldipine is officially indicated for the treatment of hypertension (high blood pressure). However, regulatory documents describe the drug's approved use but typically do not specify its exact position (such as 'first-line' or 'second-line') within official clinical treatment guidelines.

Q: Can Nisoldipine be used in people who have diabetes?

A: Official regulatory documents do not list diabetes as an absolute restriction for using Nisoldipine. While its use is possible, the safety and effectiveness data specific to the diabetic population are not always detailed in the general labeling.

Q: What does the official patient information say about taking Nisoldipine with other blood pressure medicines?

A: Official patient information states that Nisoldipine has been used with other classes of blood pressure medications. This includes diuretics, ACE inhibitors, and beta-blocking agents. The information notes that close observation is generally recommended when this drug is combined with other blood pressure lowering agents.

Q: Can Nisoldipine affect sexual function?

A: Regulatory safety documents mention that gynecomastia (the enlargement of male breast tissue) has been associated with the use of calcium channel blockers. Other effects on sexual function are not frequently or commonly listed in the regulatory side effect summaries.

Q: Does taking Nisoldipine affect my ability to drive or operate machinery?

A: Official warnings state that because Nisoldipine may cause side effects such as dizziness, lightheadedness, or fainting, these effects should be monitored. It is generally advised not to engage in activities like driving, using machinery, or performing tasks that require mental alertness until the drug’s effects are known.

Q: What are the signs of a potential allergic reaction to Nisoldipine?

A: Signs of a potential serious allergic reaction include swelling of the face, eyes, lips, tongue, arms, or legs. Regulatory documents describe these and difficulty breathing or swallowing as symptoms that may indicate a need for urgent care.

Q: Does Nisoldipine require regular blood tests or monitoring?

A: Official regulatory information indicates that Nisoldipine is not known to interfere with the interpretation of standard laboratory tests. The official label does not generally mandate specific regular blood tests for monitoring the drug itself.

How should Nisoldipine be stored and disposed of?

How to Store and Dispose of Nisoldipine?

Nisoldipine extended-release tablets must be stored at controlled room temperature, specifically between 20^circC and 25^circC (68^circF to 77^circF), with minimal excursions permitted. The medication must be kept in its original container, which should be tightly closed.

Storage Protection

The product must be protected from light and excess moisture to maintain its stability and effectiveness. For safety, Nisoldipine must always be stored securely out of the reach of children.

Disposal Requirements

Unused or expired nisoldipine must be disposed of in accordance with local regulatory requirements for medicinal products. Regulatory documents generally advise against discarding the medicine by flushing it down the toilet or pouring it into a drain, unless officially instructed to do so by a local take-back program.

Nisoldipine